Download Files:
Products Details
Product Description
– JNK-IN-12 (compound P2) is a mitochondrial-targeted JNK inhibitor (IC50=66.3 nM), consisting of a mitochondrial-specific cell-penetrating peptide and a specific inhibitor of JNK, SP600125 (HY-12041). JNK-IN-12 doesn’t inhibit nuclear JNK signaling, but does inhibit mitochondrial JNK phosphorylation. JNK-IN-12 helps to improve the Parkinson’s disease (PD) both in vitro and in vivo[1].
Web ID
– HY-155077
Shipping
– Room temperature
Molecular Formula
– C56H82N16O7
References
– [1]Zhou Z, et al. Design and Synthesis of a Mitochondrial-Targeted JNK Inhibitor and Its Protective Effect on Parkinson’s Disease Phenotypes. Chembiochem. 2023 Jul 3;24(13):e202200748.
Molecular Weight
– 1091.35
SMILES
– O=C1C2=C(NCCNC(CCCC3=CN(CCCC(N[C@H](C(N[C@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(N)=O)CCCCN)=O)CC4CCCCC4)=O)=O)CC5CCCCC5)=O)N=N3)=O)C=CC=C2C6=NNC7=C6C1=CC=C7
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– JNK
Pathway
– MAPK/ERK Pathway
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
